These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29077766)

  • 1. Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals.
    Rozera G; Fabbri G; Lorenzini P; Mastrorosa I; Timelli L; Zaccarelli M; Amendola A; Vergori A; Plazzi MM; Cicalini S; Antinori A; Capobianchi MR; Abbate I; Ammassari A
    PLoS One; 2017; 12(10):e0187095. PubMed ID: 29077766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.
    Parisi SG; Andreis S; Basso M; Cavinato S; Scaggiante R; Franzetti M; Andreoni M; Palù G; Cattelan AM
    Med Microbiol Immunol; 2017 Dec; 206(6):419-428. PubMed ID: 28864951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
    Gandhi RT; Coombs RW; Chan ES; Bosch RJ; Zheng L; Margolis DM; Read S; Kallungal B; Chang M; Goecker EA; Wiegand A; Kearney M; Jacobson JM; D'Aquila R; Lederman MM; Mellors JW; Eron JJ;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):229-35. PubMed ID: 22083073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
    d'Arminio Monforte A; Cozzi-Lepri A; Ceccherini-Silberstein F; De Luca A; Lo Caputo S; Castagna A; Mussini C; Cingolani A; Tavelli A; Shanyinde M; Gori A; Girardi E; Andreoni M; Antinori A; Puoti M;
    PLoS One; 2017; 12(5):e0177402. PubMed ID: 28520749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual-target approach in viral HIV-1 viremia testing: An added value to virological monitoring?
    Amendola A; Sberna G; Forbici F; Abbate I; Lorenzini P; Pinnetti C; Antinori A; Capobianchi MR
    PLoS One; 2020; 15(2):e0228192. PubMed ID: 32023284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
    J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV tropism switch in archived DNA of HIV-HCV subjects successfully treated with direct-acting antivirals for HCV infection.
    Basso M; Zago D; Scaggiante R; Cavinato S; Pozzetto I; Stagni C; Parisatto B; Cattelan AM; Battagin G; Sarmati L; Parisi SG
    Sci Rep; 2021 Apr; 11(1):9274. PubMed ID: 33927306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts.
    N'takpe JB; Gabillard D; Moh R; Gardiennet E; Emieme A; Badje A; Kouame GM; Toni TD; Karcher S; Carrou JL; Ménan H; Danel C; Eholie SP; Rouzioux C; Anglaret X
    EBioMedicine; 2020 Jun; 56():102815. PubMed ID: 32512517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
    Buzón MJ; Codoñer FM; Frost SD; Pou C; Puertas MC; Massanella M; Dalmau J; Llibre JM; Stevenson M; Blanco J; Clotet B; Paredes R; Martinez-Picado J
    PLoS Pathog; 2011 Oct; 7(10):e1002314. PubMed ID: 22046128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
    Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
    J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of raltegravir on HIV-1 RNA and DNA forms following initiation of antiretroviral therapy in treatment-naive patients.
    Stephan C; Baldauf HM; Barry J; Giordano FA; Bartholomae CC; Haberl A; Bickel M; Schmidt M; Laufs S; Kaderali L; Keppler OT
    J Antimicrob Chemother; 2014 Oct; 69(10):2809-18. PubMed ID: 24962031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal variation in human immunodeficiency virus long terminal repeat methylation in individuals on suppressive antiretroviral therapy.
    Cortés-Rubio CN; Salgado-Montes de Oca G; Prado-Galbarro FJ; Matías-Florentino M; Murakami-Ogasawara A; Kuri-Cervantes L; Carranco-Arenas AP; Ormsby CE; Cortés-Rubio IK; Reyes-Terán G; Ávila-Ríos S
    Clin Epigenetics; 2019 Sep; 11(1):134. PubMed ID: 31519219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA.
    Lam YM; McBride KL; Amin J; Cordery DV; Kelleher AD; Cooper DA; Koelsch KK
    PLoS One; 2012; 7(3):e31990. PubMed ID: 22396745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy.
    Farcomeni S; Moretti S; Fimiani C; Sulekova LF; Vescio F; Sernicola L; Maggiorella MT; Remoli AL; Picconi O; Mosca L; Esvan R; Biliotti E; Ciccozzi M; Sgarbanti M; Taliani G; Borsetti A
    Pathogens; 2021 Nov; 10(11):. PubMed ID: 34832642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
    Hlavay BA; Zhuo R; Ogando N; Charlton C; Stapleton JT; Klein MB; Power C
    J Clin Virol; 2023 May; 162():105445. PubMed ID: 37043902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.
    Nunnari G; Otero M; Dornadula G; Vanella M; Zhang H; Frank I; Pomerantz RJ
    AIDS; 2002 Jan; 16(1):39-45. PubMed ID: 11741161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
    Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
    Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.
    de Mendoza C; Martin-Carbonero L; Barreiro P; de Baar M; Zahonero N; Rodriguez-Novoa S; Benito JM; González-Lahoz J; Soriano V
    AIDS; 2007 Mar; 21(5):583-8. PubMed ID: 17314520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
    Chary A; Winters MA; Eisen R; Knight TH; Asmuth DM; Holodniy M
    J Med Virol; 2012 Mar; 84(3):431-7. PubMed ID: 22246828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.